Journal of Vaccine Research 2024, Vol.14, No.5, 217-230 http://medscipublisher.com/index.php/jvr 228 Covián C., Fernández-Fierro A., Retamal-Díaz A., Díaz F.E,, Vasquez A.E., Lay M.K., Riedel C.A., González P.A., Bueno S.M., and Kalergis A.M., 2019, BCG-induced cross-protection and development of trained immunity: implication for vaccine design, Frontiers in Immunology, 10: 2806. https://doi.org/10.3389/fimmu.2019.02806 PMID: 31849980 PMCID: PMC6896902 Elizaga M.L., Li S.Y., Kochar N.K., Wilson G.J., Allen M.A., Tieu H.V.N., Frank I., Sobieszczyk M.E., Cohen K.W., Sanchez B., Latham T.E., Clarke D.K., Egan M., Eldridge J.H., Hannaman D., Xu R., Ota-Setlik A., McElrath M.J., Hay C., and NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team, 2018, Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial, PLoS One, 13(9): e0202753. https://doi.org/10.1371/journal.pone.0202753 PMID: 30235286 PMCID: PMC6147413 Facciolà A., Visalli G., Laganà A., and Di Pietro A.D., 2022, An overview of vaccine adjuvants: current evidence and future perspectives, Vaccines, 10(5): 819. https://doi.org/10.3390/vaccines10050819 PMID: 35632575 PMCID: PMC9147349 Fierro C.A., Sarnecki M., Doua J., Spiessens B., Go O., Davies T.A., van de Dobbelsteen G., Poolman J., Abbanat D., and Haazen W., 2023, Safety, reactogenicity, immunogenicity, and dose selection of 10-valent extraintestinal pathogenic Escherichia coli bioconjugate vaccine (VAC52416) in adults aged 60-85 years in a randomized, multicenter, interventional, first-in-human, phase 1/2a study, Open Forum Infectious Diseases, 10(8): ofad417. https://doi.org/10.1093/ofid/ofad417 PMID: 37608916 PMCID: PMC10442062 Flacco M.E., Manzoli L., Rosso A., Marzuillo C., Bergamini M., Stefanati A., Cultrera R., Villari P., Ricciardi W., Ioannidis J.P.A., and Contopoulos-Ioannidis D.G., 2018, Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis, The Lancet Infectious Diseases, 18(4): 461-472. https://doi.org/10.1016/S1473-3099(18)30048-3 PMID: 29371070 Folegatti P.M., Ewer K., Aley P., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S.N., Bittaye M., Clutterbuck E., Dold C., Faust S., Finn A., Flaxman A.L., Hallis B., Heath P., Jenkin D., Lazarus R., Makinson R., Minassian A.M., Pollock K.M., Ramasamy M., Robinson H., Snape M., Tarrant R., Voysey M., Green C., Douglas A.D., Hill A.V.S., Lambe T., Gilbert S.C., Pollard A.J., and Oxford COVID Vaccine Trial Group, 2020, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, Lancet, 396(10249): 467-478. https://doi.org/10.1016/S0140-6736(20)31604-4 PMID: 32702298 PMCID: PMC7445431 Heath P.T., Galiza E.P., Baxter D.N., Boffito M., Browne D., Burns F., Chadwick D.R., Clark R., Cosgrove C., Galloway J., Goodman A.L., Heer A., Higham A., Iyengar S., Jamal A., Jeanes C., Kalra P.A., Kyriakidou C., McAuley D.F., Meyrick A., Minassian A.M,, Minton J., Moore P., Munsoor I., Nicholls H., Osanlou O., Packham J., Pretswell C.H., Ramos A.S.F., Saralaya D., Sheridan R.P., Smith R., Soiza RL.., Swift P.A., Thomson E.C., Turner J., Viljoen M.E., Albert G., Cho I., Dubovsky F., Glenn G., Rivers J., Robertson A., Smith K., and Toback S., 2019nCoV-302 Study Group, 2021, Safety and efficacy of NVX-CoV2373 Covid-19 vaccine, The New England Journal of Medicine, 385(13): 1172-1183. https://doi.org/10.1056/NEJMoa2107659 PMID: 34192426 PMCID: PMC8262625 Hsieh S.M., Liu M.C., Chen Y.H., Lee W.S., Hwang S.J., Cheng S.H., Ko W.C., Hwang K.P., Wang N.C., Lee Y.L., Lin Y.L., Shih S.R., Huang C.G., Liao C.C., Liang J.J., Chang C.S., Chen C., Lien C.E., Tai I.C., and Lin T.Y., 2021, Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan, The Lancet Respiratory Medicine, 9(12): 1396-1406. https://doi.org/10.1016/S2213-2600(21)00432-7 PMID: 34655522 PMCID: PMC8514195 Jongo S.A., Church L.W.P., Nchama V.U.N.N., Hamad A., Chuquiyauri R., Kassim K.R., Athuman T., Deal A., Natasha K.C., Mtoro A., Mpina M., Nyakarungu E., Bidjimi G.O., Owono M.A., Mayé E.R.M.., Mangue M.E.O., Okomo G.N.N., Pasialo B.E.T., Mandumbi D.M.O., Mikue M.S.A., Mochomuemue F.L., Obono M.O., Besahá J.C.M., Bijeri J.R., Abegue G.M., Veri Y.R., Bela I.T., Chochi F.C., Sánchez J.E.L., Pencelli V., Gayozo G., Nlang J.A.E.M., Schindler T., James E.R., Abebe Y., Lemiale L., Stabler T.C., Murshedkar T., Chen M.C., Schwabe C., Ratsirarson J., Rivas M.R., Ayekaba M.O., Milang D.V.N., Falla C.C., Phiri WP.., García G.A., Maas C.D,, Nlavo B.M., Tanner M., Billingsley P.F., Sim B.K.M., Daubenberger C., Hoffman S.L., Abdulla S., and Richie T.L., 2022, Multi-dose priming regimens of PfSPZ vaccine: safety and efficacy against controlled human malaria infection in equatoguinean adults, The American Journal of Tropical Medicine and Hygiene, 106(4): 1215-1226. https://doi.org/10.4269/ajtmh.21-0942 PMID: 35130487 PMCID: PMC8991366 Jr Frenck R.W., Ervin J., Chu L., Abbanat D., Spiessens B., Go O., Haazen W., van den Dobbelsteen G., Poolman J., Thoelen S., and de Palacios P.i., 2019, Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial, The Lancet Infectious Diseases, 19(6): 631-640. https://doi.org/10.1016/S1473-3099(19)30084-1 PMID: 31079947
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==